Baseline predictors of tolerability to carvedilol in patients with chronic heart failure

Heart

Volumn 84, Issue 6, 2000, Pages 615-619

  Krum, H ^a   Ninio, D ^a   MacDonald, P ^b  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Carvedilol; Chronic heart failure; blockade

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; UREA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UREA BLOOD LEVEL;

EID: 0033645765     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.6.615     Document Type: Article

References (12)

1. The treatment of heart failure
2. Consensus recommendations for the management of chronic heart failure
3. The pharmacology of carvedilol
4. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
5. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure
7. A randomized trial of β-blockade in heart failure: The Cardiac insufficiency bisoprolol study
8. The cardiac insufficiency bisoprolol study (CIBIS-II): A randomised trial
9. Clinical variables predicting the use of beta-blockers in heart failure: The BRING-UP study
10. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
11. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
12. Pharmacological management of chronic heart failure in Australian general practice: The cardiac awareness survey and evaluation (CASE) study